• LNP Delivery of ABE8e for COL7A1 Correction

  2026-10-08

  A 2024 Journal of Investigative Dermatology study examined lipid nanoparticles as carriers for the adenine base editor ABE8e in dystrophic epidermolysis bullosa fibroblasts, targeting pathogenic COL7A1 variants in vitro. Its significance lies in connecting nonviral mRNA delivery with sequence-level correction, while the in vitro design means that delivery, editing specificity, functional restoration, and clinical relevance require further validation.

• ORAI2 and Early Postirradiation Salivary Fibrosis

  2026-10-07

  A 2025 study identifies ORAI2-mediated store-operated calcium entry as an important driver of early postirradiation salivary-gland fibrosis and proposes an ORAI2/JNK/NFAT1/TGF-β1 signaling axis. The findings connect calcium signaling to fibrotic remodeling and improved salivary flow in a mouse model, while also highlighting the limits of pharmacologic and preclinical evidence.

• Sulfo-NHS-SS-Biotin: Reading Cell-Surface Evidence

  2026-10-07

  Sulfo-NHS-SS-Biotin offers a reversible way to interrogate amine-bearing proteins at the cell surface. This article explains how its chemistry can inform glycoRNA–RNA-binding protein research while distinguishing direct findings from interpretation and experimental limitations.

• Rimonabant (SR141716): Research Context and Evidence

  2026-10-06

  Rimonabant is a selective CB1 antagonist used as a pharmacological probe in endocannabinoid-system, appetite-regulation, and obesity research. The supplied evidence supports mechanistic investigation but does not establish clinical efficacy or broader therapeutic applications.

• GS967 and Cardiac Late Sodium Current Research

  2026-10-06

  GS967 is a research compound used to investigate pathological late sodium current in cardiac models. Evidence from a 2024 aging study supports a mechanistic relationship between Nav1.5 Ser571 phosphorylation, increased late sodium current, delayed ventricular repolarization, and impaired relaxation, while direct evidence for GS967 in human disease remains limited.

• Rimonabant (SR141716): Research Context and Evidence

  2026-10-05

  Rimonabant, also known as SR141716, is a selective CB1 receptor antagonist used as a research tool for studying endocannabinoid signaling, food reward, energy balance, and cannabinoid withdrawal. Evidence supports its value as a mechanistic probe, particularly in animal models, but findings do not establish clinical benefit or justify therapeutic use. This overview compares receptor pharmacology with behavioral evidence, highlights sex-dependent withdrawal findings, and explains major limitations involving model choice, psychiatric safety, and source provenance.

• Sequencing Waldenström Therapies Through Genomics

  2026-10-05

  This 2021 review argues that therapy selection in Waldenström macroglobulinemia should integrate clinical presentation, patient priorities, prior treatment context, and MYD88/CXCR4 genomic status rather than follow a single universal sequence. Its key contribution is a genotype-informed framework that places ibrutinib, chemoimmunotherapy, proteasome inhibitor regimens, transplantation, and investigational agents such as mavorixafor within a disease-specific decision landscape.

• NADPH Oxidase ROS and Arterial Contraction

  2026-10-04

  Shvetsova and colleagues found that NADPH oxidase-derived reactive oxygen species enhance contraction in early postnatal rat saphenous arteries through L-type voltage-gated calcium channels rather than through Rho-kinase, PKC, or Src-kinase signaling. The study narrows the mechanistic link between vascular ROS and calcium entry while highlighting the developmental and model-specific limits of the evidence.

• MRSA Extracellular Vesicles and OSCC IL-8 Signaling

  2026-10-03

  A 2026 study reports that extracellular vesicles from methicillin-resistant Staphylococcus aureus can promote oral squamous cell carcinoma through an IL-8–CXCR1 signaling axis. Its main contribution is linking antibiotic-resistant bacteria, vesicle-mediated cargo delivery, ERK/c-Jun activation, and tumor-cell proliferation while identifying IL-8 loss and CXCR1 blockade as mechanistic tests.

• Sorafenib in Liver Cancer: Kinase–Metabolic Readouts

  2026-10-01

  Sorafenib (BAY-43-9006) is more than a standard multikinase inhibitor: it can serve as a mechanistic benchmark for separating RAF/MEK/ERK, angiogenic, and organelle-stress readouts. This article connects Sorafenib assay design with recent evidence on mitochondrial cholesterol metabolism in hepatocellular carcinoma models.

• Rimonabant (SR141716) in CB1 Withdrawal Research

  2026-10-01

  Rimonabant (SR141716) turns CB1 pharmacology into a practical challenge assay for withdrawal, appetite, inflammation, and cell-signaling studies. This guide pairs sex-aware behavioral design with formulation, dosing, and troubleshooting decisions that improve mechanistic resolution.

• Cy7 NHS Ester: Practical Labeling Guide

  2026-09-30

  Cy7 NHS ester (SKU A8109) is a sulfonated, water-soluble amino-group labeling reagent for proteins, peptides, and related biomolecules when an aqueous workflow is preferred. This guide covers preparation, conjugation, purification, and QC for near-infrared imaging; it does not establish cellular uptake, in vivo performance, or assay suitability without application-specific validation.

• Trelagliptin Succinate Research Workflows

  2026-09-30

  Trelagliptin succinate, also known as SYR-472 succinate, supports reproducible DPP-4 enzyme inhibition studies alongside cell, animal, and pharmaceutical quality workflows. This guide combines practical dosing design, stability-aware handling, validated HPLC concepts, and troubleshooting for diabetes mellitus research.

• Cediranib (AZD2171) In Vitro Research Workflows

  2026-09-29

  Cediranib (AZD2171) is a potent, orally bioavailable angiogenesis inhibitor for dissecting VEGFR signaling, endothelial responses, and tumor-associated pathway biology. This workflow emphasizes matched pathway, proliferation, and cell-death measurements so a reduced viability signal is not mistaken for a single biological mechanism.

• NHS-Biotin: Practical Protein Labeling Workflow

  2026-09-29

  NHS-Biotin provides an amine-reactive route for attaching biotin to antibodies, proteins, and other primary amine-containing biomolecules for streptavidin-based detection or purification. It is suited to irreversible labeling workflows, but not to experiments requiring site-specific control, reversible labeling, or unverified intracellular performance.

8561 records 1/571 page Next 12345 下5页 Last page